Company stock · NASDAQ · USD

VRTX

Vertex Pharmaceuticals Inc

—

Price unavailable — company details still show below

Sector: Healthcare
Industry: Biotechnology
Size: Large company
Market value: $132.9 billion
Number of shares: 253.5 million
Country: US
Went public: Jul 24, 1991
Exchange: NASDAQ
Website: vrtx.com
Next earnings: 2026-11-02 · analysts’ expected profit per share $4.86

Themes

Healthcare innovation

Compare →Earnings calendar →

Price chart Pro

Loading chart…

Company briefing

What VRTX is

Plain English context — why the name shows up in the news, and what to watch next.

In plain English

Vertex Pharmaceuticals Inc. develops specialty medicines, mainly for cystic fibrosis and other serious diseases, and is now pushing into…

Recent headlines

Live company news for VRTX — each headline includes a ClearTape brief in plain English; open the original for the full story.

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.In brief
Vertex’s revenue is heavily tied to cystic fibrosis, making up 96% of sales. The company is now working to broaden its product line beyond that single disease.
Yahoo · Oct 24, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 TranscriptIn brief
Vertex presented at the American Society of Nephrology Kidney Week 2026.
SeekingAlpha · Oct 24, 2026
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase IIIIn brief
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD. Chief Executive Officer and President Reshm
Yahoo · Oct 24, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - SlideshowIn brief
Vertex released a slide deck for its presentation at the 2026 ASN Kidney Week. The deck was published on October 23, 2026.
SeekingAlpha · Oct 23, 2026
Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?In brief
Vertex’s stock is currently priced high. Analysts are questioning whether the price will come down in the future.
Yahoo · Oct 23, 2026
Vertex Pharmaceuticals Announces Phase 3 RAINIER Results Supporting Potential Of Povetacicept In IgA Nephropathy Published In The New England Journal Of Medicine; Vertex’s Povetacicept Shows 49.8% Greater Proteinuria Reduction vs. Placebo In Phase 3 IgAN Trial; FDA Decision Expected November 30In brief
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s
Benzinga · Oct 23, 2026
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?In brief
Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $156.51 as of October 20th 2026. GILD’s trailing and forward P/E were 17.84 and 15.55 respectively […]
Yahoo · Oct 22, 2026
Vertex Pharmaceuticals Receives FDA's Orphan Designation For Atumelnant To Treat Endogenous Cushing’s SyndromeIn brief
Vertex received FDA orphan designation for Atumelnant, a treatment for endogenous Cushing’s syndrome. The designation is listed on the FDA’s orphan drug database.
Benzinga · Oct 22, 2026

Same sector

Similar companies · Healthcare

% is today vs yesterday’s close

Latest on this name

Insights & deeper context

2 recent cards — open any for the full deeper dive.

CompanyShort-termNeutralDays to weeksBenzingaGOOGL VRTX OKTA PCVX

Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday

In brief

Analysts updated price targets for a dozen stocks on Monday, including a modest $5 lift for Alphabet Inc.

Open card →

EconomyShort-termNeutralDays to weeksBenzingaAMZN AAPL VRTX TSN MAR

Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone

In brief

The Nasdaq's 1% gain on Friday was led by Amazon's 15% surge, but the CNN Money Fear and Greed index remains in the 'Fear' zone, indicating caution among investors.

Open card →

Company reports

Official filings (US SEC and linked cards)

No filings here yet

Official report cards for VRTX will show up here when available.

Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.

VRTX

In plain English

Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday

01In brief

Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone

01In brief

In brief

In brief